Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases

World J Gastroenterol. 2022 Jul 7;28(25):2843-2853. doi: 10.3748/wjg.v28.i25.2843.

Abstract

Patients with inflammatory bowel disease (IBD) are more likely to have concurrent immune-mediated inflammatory diseases (IMIDs) than those without IBD. IMIDs have been observed to alter the phenotype and outcomes of IBD in recent studies. Several studies have found that IBD patients with concurrent IMIDs may have more extensive or severe disease phenotypes, and are considered to be at increased risk of requiring biologics and IBD-related surgeries, suggesting that having multiple IMIDs is a poor prognostic factor for IBD. Furthermore, IBD patients with primary sclerosing cholangitis and Takayasu arteritis are reported to have unique endoscopic phenotypes, suggesting concurrent IMIDs can influence IBD phenotype with specific intestinal inflammatory distributions. In this review, we discuss the pathogenesis, disease phenotypes, and clinical outcomes in IBD patients with concomitant IMIDs.

Keywords: Concurrent immune-mediated inflammatory diseases; Inflammatory bowel disease; Outcomes; Phenotypes.

Publication types

  • Review

MeSH terms

  • Cholangitis, Sclerosing* / complications
  • Cholangitis, Sclerosing* / pathology
  • Humans
  • Inflammatory Bowel Diseases* / pathology
  • Phenotype